Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer

IUBMB Life

Volumn 62, Issue 5, 2010, Pages 394-399

  Eissa, Sanaa ^a   Shabayek, Marwa I ^b   Ismail, Manal F ^c   El Allawy, Raouf M ^b   Hamdy, Mohamed A ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Bladder cancer; Cytology; RT nested PCR; Survivin; TIMP 2

Indexed keywords

MESSENGER RNA; SURVIVIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; CYSTITIS; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CYSTITIS; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; SCHISTOSOMIASIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

NUCLEOPOLYHEDROVIRUS;

EID: 77953597959     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.325     Document Type: Article

References (26)

1. Lotan, Y., Svatak, R. S., and Matas, N. (2008) Screening for bladder cancer. World J. Urol. 26, 3-8.
2. Khaled, H. M.(2005) Systemic management of bladder cancer in Egypt. J. Egypt Natl. Canc. Inst. 17, 127-131.
3. Frampton, J. E. and Plosker, G. L. (2006) Hexyl aminolevulinate in the detection of bladder cancer. Drugs 66, 571-578.
4. Li, F. and Ling, X. (2006) Survivin study: an update of "what is the next wave"? J. Cell Physiol. 208, 476-486.
5. Tanaka, K., Iwamoto, S., Gon, G., Nohara, T., Iwamoto, M., and Tanigawa, N. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6, 127-134.
6. Imren, S., Kohn, D. B., Shimada, H., Blavier, L., and De-Clerck, Y. A. (1996) Overexpression of tissue inhibitor of metalloproteinase-2 by retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 56, 2891-2895.
7. Kanayama, H., Yokota, K., Kurokawa, Y., Murakami, Y., Nishitani, M., and Kagawa, S. (1998) Prognostic values of matrix metalloproteinase-2 and tissue inhibitor metalloproteinase-2 expression in bladder cancer. Cancer 82, 1359-1366.
8. Greene, F. L., Page, D. L., Flemming, I. D., Fritz, A. G., Balch, C. M., Haller, D. G., and Morrow, M. (2002) American Joint Committee on Cancer Staging Manual, Vol.6. pp. 337-346, Springer-Verlag, New York.
9. Yorukoglu, K., Tuna, B., Dikicioglu, E., Duzcan, E., Isisag, A., Sen, S., Mungan, U., and Kirkali, Z. (2003) Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch. 443, 734-740.
10. Bradford, M. M. (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
11. Papanicolaou, G. N. and Marshall, V. F. (1954) Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 101, 519-520.
12. Eissa, S., Kassim, S., and El-Ahmady, O. (2003) Detection of bladder tumors: role of cytology, morphology-based assays, biochemical and molecular markers. Curr. Opin. Obstet. Gynecol. 15, 395-403.
13. Smith, S. D., Wheeler, M. A., Plescia, J., Colberg, J. W., Weiss, R. M., and Altieri, D. C. (2001) Urine detection of survivin and diagnosis of bladder cancer. JAMA 285, 324-328.
14. Ambrosini, G., Adida, C., and Altieri, D. C. (1997) A novel anti-apo-ptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921.
15. Moussa, O., Abol-Enein, H., Bissada, N. K., Keane, T., Ghoneim, M. A., and Watson, D. K. (2006) Evaluation of survivin reverse transcrip-tase- polymerase chain reaction for noninvasive detection of bladder cancer. J. Urol. 175, 2312-2316.
16. Hou, Q., He, J., Wen, G., Chen, X., and Zeng, J. (2006) Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder. Chin. Med. J. (Engl) 119, 1118-1120.
17. Shariat, S. F., Casella, R., and Plescia, J. (2004) Urine detection of sur-vivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J. Urol. 171, 626-630.
18. Sun, J., Hou, J.-Q., He, J., He, X.-F., and Wen, D.-G. (2009) Expression of survivin in urine exfoliated cells of patients with bladder transitional cell carcinoma detected by real-time PCR. Chin. J. Cancer 28, 1100-1102.
19. Grigioni, W. F., D'Errico, A., Fiorentino, M., Baccarini, P., Onisto, M., Caenazzo, C., et al. ( 1994) Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties. Diagn. Mol. Pathol. 3, 163-169.
20. Ray, J. M. and Stetler-Stevenson, W. G. (1994) The role of matrix met-alloproteases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur. Respir. J. 7, 2062-2072.
21. Lambert, E., Dasse, E., Haye, B., and Petitfrere, E. (2004) TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol. 49, 187-198.
22. Xu, K., Hov, S., and Du, Z. (2002) Prognostic value of matrix metallo-proteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma. Chin. Med. J. (Engl) 115, 743-745.
23. Grignon, D. J., Sakr, W., Toth, M., Ravery, V., Angulo, J., Shamsa, F., Pontes, J. E., Crissman, J. C., and Fridman, R. (1996) High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 1, 1654-1659.
24. Davidson, B., Goldberg, I., Kopolovic, J., Lerner-Geva, L., Gotlieb, W. H., Ben-Baruch, G., and Reich, R. (1999) MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma: a clinicopath-ologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol. Oncol. 73, 372-382.
25. Hayakawa, T., Yamashita, K., Ohuchi, E., and Shinagawa, A. (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2. J. Cell Sci. 107, 2373-2379.
26. Kallakury, B. V., Karikehalli, S., Haholu, A., Sheehan, C. E., Azumi, N., and Ross, J. S. (2001) Increased expression of matrix metalloprotei-nases-2 and tissue inhibitors of metalloproteinases-1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin. Cancer Res. 10, 3113-3119.